Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Conditions
Interventions
9-ING-41
Retifanlimab
+2 more
Locations
2
United States
Kansas University Cancer Center
Fairway, Kansas, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
January 26, 2022
Primary Completion Date
December 20, 2022
Completion Date
February 4, 2024
Last Updated
July 17, 2025
NCT06423326
NCT04389632
NCT04895709
NCT05825066
NCT07409272
NCT04605913
Lead Sponsor
Anwaar Saeed
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions